Lördag 21 December | 17:35:04 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-28 08:30 Bokslutskommuniké 2024
2024-11-29 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-27 - X-dag ordinarie utdelning INIT 0.00 SEK
2024-05-24 - Årsstämma
2024-05-10 - Kvartalsrapport 2024-Q1
2024-02-23 - Bokslutskommuniké 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-29 - X-dag ordinarie utdelning INIT 0.00 SEK
2023-05-26 - Årsstämma
2023-05-05 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-04 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-23 - X-dag ordinarie utdelning INIT 0.00 SEK
2022-05-20 - Årsstämma
2022-05-06 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-19 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-31 - X-dag ordinarie utdelning INIT 0.00 SEK
2021-05-28 - Årsstämma
2021-05-25 - Kvartalsrapport 2021-Q1
2021-05-11 - Extra Bolagsstämma 2021
2021-02-19 - Bokslutskommuniké 2020
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-25 - X-dag ordinarie utdelning INIT 0.00 SEK
2020-05-22 - Årsstämma
2020-05-22 - Kvartalsrapport 2020-Q1
2020-02-21 - Bokslutskommuniké 2019
2019-11-22 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-05-24 - X-dag ordinarie utdelning INIT 0.00 SEK
2019-05-23 - Årsstämma
2019-05-23 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-11-23 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-28 - X-dag ordinarie utdelning INIT 0.00 SEK
2018-05-25 - Årsstämma
2018-05-25 - Kvartalsrapport 2018-Q1
2018-03-01 - Extra Bolagsstämma 2017
2018-02-21 - Bokslutskommuniké 2017
2017-11-24 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-26 - Kvartalsrapport 2017-Q1
2017-05-17 - X-dag ordinarie utdelning INIT 0.00 SEK
2017-05-16 - Årsstämma

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Initiator Pharma är verksamma inom bioteknik. Idag innehas störst affärsinriktning mot utveckling av läkemedelskandidater som används vid behandling av erektil dysfunktion hos män. Bolaget har för tillfället läkemedel under testning i klinisk fas för patienter som inte svarar på PDE5i läkemedel. Initiator Pharma kom till via en spin-off från Saniona och har idag sitt huvudkontor i Åbyhøj.
2023-09-25 08:30:00

The AGM held on May 26, 2023 approved two long-term incentive programs (“LTI2023”), one for Management and leading employees and one for board members.

LTI2023 for Management and leading employees:
Under the program for Management and leading employees the board is authorized to allow participants in the program to acquire up to 108.500 ordinary shares in the market at market price (“Investment Shares”) until September 30, 2023, with each Investment Share carrying the right to subscribe for 1 new share at par value at the next AGM providing that the individual owning the Investment Share is still with the company at the time (“Matching Share”). Each Investment Share is also entitled to subscribe for between 0 and 5 new shares at par value during 30 trading days after December 31, 2025, depending on the development of Initiator’s share price in the period between May 26 2023 and December 31 2025. The maximum potential dilution under the approved program is 651,000 shares, representing approx. 1.2% of currently issued number of shares.

The board has decided to allocate a total of maximum 108.500 shares that can be purchased under this program, representing a potential dilution of 651.000 shares and approx. 1.20% of currently issued number of shares. By the end of the allowable investment period the maximum number of shares has been purchased in the market.

LTI2023 for Board members:
Under the program for Board members the board is authorised to allow participants in the program to acquire up to 23.000 ordinary shares in the market at market price (“Investment Shares”) until September 30, 2023, with each Investment Share carrying the right to acquire 1 new share from the company at par value at the next AGM providing that the individual owning the Investment Share is still with the company at the time (“Matching Share”). Each Investment Share is also entitled to acquire between 0 and 5 new shares from the company at par value during 30 trading days after December 31, 2025, depending on the development of Initiator’s share price in the period between May 26 2023 and December 31 2025. The maximum potential dilution under the approved program is 138,000 shares, representing approx. 0.3% of currently issued number of shares.

The board has decided to allocate a total of maximum 23.000 shares that can be purchased under this program, representing a potential dilution of 138.000 shares and approx. 0.3% of currently issued number of shares. By the end of the allowable investment period the maximum number of shares has been purchased in the market.

In the table below an overview of shares and warrants held by the board of directors, executive management and key employees is presented. The overview comprises warrants from the incentive programmes for 2021, 2022 and 2023, respectively.

IndividualPositionSharesWarrants


Total
Shares and warrants
Pct
fully diluted



202120222023Total
warrants


Magnus PerssonBoard member267 18650 00012 50048 000110 500377 6860,72%
Henrik MoltkeBoard member139 10635 00035 00030 000100 000239 1060,46%
Peter HolmBoard member-------
Annette ColinBoard member25 00035 00015 00030 00080 000105 0000,20%
Gunilla EkströmBoard member19 000-35 00030 00065 00084 0000,16%
Total BoD450 292120 00097 500138 000355 500805 7921,53%
Claus OlesenCEO and board member1 137 438300 000175 000180 000655 0001 792 4383,42%
Other mgmt. and key employees1 824 306330 000375 000471 0001 176 0003 000 3065,72%
Total Mgmt and key employees3 964 038630 000550 000651 0001 831 0004 792 7449,14%
Total BoD, Mgmt and key employees4 414 330750 000647 500789 0002 186 5005 598 53610,67%